Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris

Daix (France), February 10, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the French market authority (Autorité des Marchés Financiers, or AMF) approved a prospectus under number 20-034 on February 7, 2020 in the context of the admission to trading of new shares on the regulated market of Euronext in Paris. 3,778,338 new shares are issued by way of a capital increase without the exercise of preemptive subscription rights in favor of categories of persons with specific characteristics for an amount of €15 million for a subscription price of €3.97 each (including premium).

The prospectus includes:

• the universal registration document filed with the AMF on February 7, 2020 under no D.20-0038;
• the securities note; and
• the summary of the prospectus (included in the securities note).

These documents may be consulted on the Company’s website at , in the “Investors” section, and on the AMF’s website at -france.org. Printed copies of the universal registration document are also available to the public free of charge and upon request at the Company’s headquarters located 50 Rue de Dijon, 21121 Daix, France.

About Inventiva 

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

Leveraging its significant expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates – lanifibranor and odiparcil – in non-alcoholic steatohepatitis (“NASH”) and mucopolysaccharidosis (“MPS”), respectively, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease. Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of this disease for which there are currently no approved therapies.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the positive results of the Phase IIa clinical trial in adult MPS VI patients published at the end of 2019.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic partnership with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development phase of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration entitles Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial objectives, in addition to royalties on any approved products resulting from this partnership.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology a well as in clinical development. It also owns an extensive chemical library of approximately 240,000 pharmacologically relevant molecules, around 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012).  

Contacts 

Inventiva

Frédéric Cren

Chairman & CEO



00

Brunswick Group

Yannick Tetzlaff / Tristan Roquet Montegon /

Aude Lepreux

Media relations



83

Attachment